Comparative Pharmacology
Head-to-head clinical analysis: KLOR CON M15 versus KLOTRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOR CON M15 versus KLOTRIX.
KLOR-CON M15 vs KLOTRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation; it is necessary for conduction of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, maintenance of normal renal function, acid-base balance, and carbohydrate metabolism.
KLOTRIX is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The thiazide diuretic increases sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney.
Oral: 15 mEq (1 tablet) once daily or as directed; range 15-100 mEq/day divided doses. Maximum 150 mEq/day.
Adults: 500-1000 mg orally every 6 hours; maximum 4000 mg/day.
None Documented
None Documented
Not applicable; potassium is not eliminated by first-order kinetics. Serum potassium decline depends on redistribution and renal function, with a half-life of approximately 1-1.5 hours for acute redistribution but prolonged in renal impairment.
Terminal half-life 12 hours; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min)
Renal: >90% as potassium ions; fecal: <5%; biliary: negligible.
Renal 70% as unchanged drug, fecal 30% via biliary secretion
Category C
Category C
Potassium Supplement
Potassium Supplement